Patrick Dolezal
Stock Analyst at LifeSci Capital
(4.52)
# 1,053
Out of 5,060 analysts
218
Total ratings
39.9%
Success rate
15.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Dolezal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTVT vTv Therapeutics | Reiterated: Buy | $60 | $26.45 | +126.89% | 2 | Oct 5, 2026 | |
| IMMX Immix Biopharma | Reiterated: Buy | $24 | $7.98 | +200.75% | 4 | Oct 3, 2026 | |
| RCKT Rocket Pharmaceuticals | Reiterated: Buy | $12 | $2.18 | +450.46% | 48 | Oct 2, 2026 | |
| KOD Kodiak Sciences | Reiterated: Buy | $85 → $145 | $85.75 | +69.10% | 13 | Sep 28, 2026 | |
| SRZN Surrozen | Rated: Buy | $46 → $54 | $23.44 | +130.38% | 9 | Sep 26, 2026 | |
| ENTX Entera Bio | Initiated Coverage: Buy | $10 | $2.68 | +273.13% | 1 | Sep 23, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $104 | $21.08 | +393.36% | 14 | Sep 8, 2026 | |
| ACHV Achieve Life Sciences | Reiterated: Buy | $17 | $6.38 | +166.46% | 5 | Sep 3, 2026 | |
| IBIO iBio, Inc. | Reiterated: Buy | $5 | $0.7663 | +552.49% | 13 | Aug 28, 2026 | |
| SLGL Sol-Gel Technologies | Rated: Buy | $184 → $195 | $64.25 | +203.50% | 4 | Aug 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 → $63 | $23.25 | +170.97% | 13 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $91 → $121 | $49.63 | +143.80% | 8 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $41 | $7.29 | +462.41% | 10 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 | $68.07 | n/a | 21 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $18.23 | n/a | 25 | Nov 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $2.00 | n/a | 12 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $16 | $0.3807 | n/a | 5 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $27.53 | n/a | 1 | Dec 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $25 | $2.94 | n/a | 2 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €10.00 → €25.00 | €2.74 | n/a | 8 | Jun 16, 2020 |
vTv Therapeutics
Oct 5, 2026
Reiterated: Buy
Price Target: $60
Current: $26.45
Upside: +126.89%
Immix Biopharma
Oct 3, 2026
Reiterated: Buy
Price Target: $24
Current: $7.98
Upside: +200.75%
Rocket Pharmaceuticals
Oct 2, 2026
Reiterated: Buy
Price Target: $12
Current: $2.18
Upside: +450.46%
Kodiak Sciences
Sep 28, 2026
Reiterated: Buy
Price Target: $85 → $145
Current: $85.75
Upside: +69.10%
Surrozen
Sep 26, 2026
Rated: Buy
Price Target: $46 → $54
Current: $23.44
Upside: +130.38%
Entera Bio
Sep 23, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $2.68
Upside: +273.13%
Structure Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $104
Current: $21.08
Upside: +393.36%
Achieve Life Sciences
Sep 3, 2026
Reiterated: Buy
Price Target: $17
Current: $6.38
Upside: +166.46%
iBio, Inc.
Aug 28, 2026
Reiterated: Buy
Price Target: $5
Current: $0.7663
Upside: +552.49%
Sol-Gel Technologies
Aug 22, 2026
Rated: Buy
Price Target: $184 → $195
Current: $64.25
Upside: +203.50%
Aug 11, 2026
Reiterated: Buy
Price Target: $65 → $63
Current: $23.25
Upside: +170.97%
Aug 8, 2026
Rated: Buy
Price Target: $91 → $121
Current: $49.63
Upside: +143.80%
Aug 8, 2026
Reiterated: Buy
Price Target: $45 → $41
Current: $7.29
Upside: +462.41%
Dec 11, 2023
Rated: Buy
Price Target: $60
Current: $68.07
Upside: n/a
Nov 11, 2023
Reiterated: Buy
Price Target: $6
Current: $18.23
Upside: n/a
Aug 10, 2023
Rated: Buy
Price Target: $14
Current: $2.00
Upside: n/a
Mar 9, 2023
Reiterated: Buy
Price Target: $17 → $16
Current: $0.3807
Upside: n/a
Dec 11, 2022
Reiterated: Buy
Price Target: $39
Current: $27.53
Upside: n/a
Mar 8, 2021
Reiterated: Buy
Price Target: $27 → $25
Current: $2.94
Upside: n/a
Jun 16, 2020
Reiterated: Buy
Price Target: €10.00 → €25.00
Current: €2.74
Upside: n/a